Abram P et al. Case studies of fulvestrant (“Faslodex”) in postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;31(Suppl 2):17-25. Abstract

Bajetta E et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-61. Abstract

Bertelli G. Sequencing of aromatase inhibitors. Br J Cancer 2005;93(Suppl 1):6-9. Abstract

Buzdar AU, Blumenschein GR et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol 1979;12(1):27-40. Abstract

Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 6052.

Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;31(4):274-82. Abstract

El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005;14(5):368-74. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract

Gradishar WJ, Sahmoud T. Current and future perspectives on fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):23-9. Abstract

Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Howell A. New developments in the treatment of postmenopausal breast cancer. Trends Endocrinol Metab 2005;16(9):420-8. Abstract

Jelovac D et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65(12):5439-44. Abstract

Johnston SR et al. Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005;95(1-5):173-81. Abstract

Johnston SR et al. Life following aromatase inhibitors — Where now for endocrine sequencing? Breast Cancer Res Treat 2005;93(Suppl 1):19-25. Abstract

Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl 1):9-14. Abstract

Jordan VC et al. The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast 2005;14(6):624-30. Abstract

Juan O et al. Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED). Breast Cancer Res Treat 1999;53(2):105-12. Abstract

Lee SH et al. Capecitabine monotherapy in patients with anthracycline- and taxanepretreated metastatic breast cancer. Med Oncol 2004;21(3):223-31. Abstract

Leonard R et al. Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda). Semin Oncol 2004;31(5 Suppl 10):21-8. Abstract

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Rivera E et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 2002;8(1):2-9. Abstract

Robertson JF et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169-74. Abstract

Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004;18(9):1161-8, 1173. Abstract